pravastatin has been researched along with natriuretic peptide, c-type in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adams, V; Erbs, S; Goettsch, W; Hambrecht, R; Holtz, J; Krekler, M; Kuss, O; Lenk, K; Mohr, FW; Morawietz, H; Schubert, A; Schuler, G | 1 |
1 trial(s) available for pravastatin and natriuretic peptide, c-type
Article | Year |
---|---|
Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Biphenyl Compounds; Blood Pressure; Cholesterol; Cholesterol, LDL; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Elective Surgical Procedures; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Irbesartan; Mammary Arteries; Membrane Glycoproteins; Muscle, Smooth, Vascular; NADPH Oxidase 2; NADPH Oxidases; Natriuretic Peptide, C-Type; Nitric Oxide Synthase Type III; Oxidative Stress; Polymerase Chain Reaction; Pravastatin; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; RNA, Messenger; Scavenger Receptors, Class E; Tetrazoles | 2006 |